ERBB2 and breast carcinoma: Based on the modified 2007 ASCO/CAP guidelines for breast cancer, a new set of HER2 testing algorithm and scoring criteria have been proposed for routine pathological evaluation of endometrial serous carcinoma, helping to select patients eligible for antiHER2 therapies.